Cellular Therapy For OA Of The Knee: The Path to Clinical Validation And Translation

When:  Oct 6, 2021 from 09:00 to 10:30 (PT)
Thursday, October 6 - 9:00 PDT / 12:00 EDT
What time is this for me?

Cellular Therapy For OA Of The Knee: The Path to Clinical Validation And Translation

An ISCT Orthopedic and Musculoskeletal Therapies Committee Webinar

This is an ISCT Member Exclusive Webinar
Please ensure that you sign in to access registration.

Webinar Description:

This webinar will provide participants with an update on progress in the field of MSC-based cellular therapy in osteoarthritis; this includes:

  1. An overview of cells used for therapy
  2. Preclinical studies
  3. Methodology to initiate clinical trials (indications, controls, trial duration)
  4. Critical clinical parameters for the follow-up and critical endpoints;
  5. Compare published and ongoing trials in the EU, US and Asia.
The webinar is targeted for the needs of clinicians, scientists, product developers, as well as the regulatory community in the field of musculoskeletal medicine. The objectives of the webinar are to provide education in clinical research as well as develop new collaboration opportunities to accelerate safe and effective clinical trials.

Chaired By: 

George Muschler, MD
Cleveland Clinic
United States

Dr. Muschler is a Professor of Orthopaedic Surgery and Biomedical Engineering at the Cleveland Clinic, with a clinical practice that integrates joint replacement, joint preservation, and bone and cartilage repair.

Dr. Muschler’s Regenerative Medicine Laboratory has earned continuous federal funding for over 25 years, focusing on stem and progenitor cell biology, tissue engineering and regenerative medicine. He has served as Vice Chair of Bioengineering (2004-2013); Director of the Orthopaedic Research Center (2005-2013), Vice Chair of the Orthopaedic and Rheumatologic Institute (2007-2013) and has served as Director of the Cleveland Clinic Joint Preservation Center since 2017.

Dr. Muschler is currently Co-Chair of the Orthopedic and Musculoskeletal Therapies Committee of the International Society for Cell and Gene Therapy (ISCT), and served as Co-Chair of the 2021 ISCT Annual meeting.



Pamela Robey, PhD
National Institute of Dental and Craniofacial Research
United States

Dr. Robey received her BA from Susquehanna University in Selinsgrove, PA, and her MS and PhD from the Catholic University in Washington, DC.

She did her post-doctoral work at the National Institute of Arthritis, Metabolism and Digestive Diseases (now the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)) on the role of defective phosphorylation of enzymes leading to lysosomal storage disease, and a staff fellowship in the National Eye Institute, where she studied retinal and ocular connective tissue diseases.

Dr. Robey joined NIDCR in 1983 and established reproducible methods for culturing human bone-forming cells, in order to study the development of mineralized matrix formation. In 1992, Dr. Robey was appointed chief of Skeletal Biology Section. Dr. Robey has served as a Co-Coordinator of the NIH Bone Marrow Stromal Cell Transplantation Center (2008-2013), and is currently the acting Scientific Director of the NIH Stem Cell Characterization Facility. 

Christian Jorgensen, MD, PhD
University Hospital Lapeyronie

Prof. Christian Jorgensen specializes in Therapeutics and Rheumatology. He is director of the IRMB, leader of the ‘Mesenchymal stem Cells, niche tissue and homeostasis’ research team and coordinator of the ECellFrance a national infrastructure dedicated to stem cell therapy and Cartigen platforms at Montpellier CHRU. He is an expert for Biologics at French National Authority or Health (HAS), and a former member of the Transparency Comity at HAS.

Pr. Jorgensen's clinical interests are in stem cells, immunology and rheumatology. He leads the clinical immunology service dedicated to biotherapy applied to Rheumatoid Arthritis and other autoimmune diseases. Pr. Jorgensen has published extensively (over 250 publications in the field of Immunology and stem cell therapy applied for rheumatic diseases), and has coordinated several national and European programs on immunology, including Genostem: Adult mesenchymal stem cells engineering for connective tissue disorders; ADIPOA project, a large scale project focusing on adipose-derived mesenchymal stem cells in osteoarthritis therapy, and the RESPINE project focusing on degenerative disc disease treatment using stem cells.

Ivan Martin, PhD
University Hospital Basel

Prof. Dr. Ivan Martin studied Biomedical Engineering at the University of Genova where he obtained his PhD in 1996. Between 1996 and 1999 he was a postdoctoral associate at Harvard/MIT. He joined the Department of Biomedicine (DBM) at the University Hospital of Basel in 1999 as leader of the Tissue Engineering Research Group, in close coordination with the surgical units.

In 2007 he was appointed Professor for Tissue Engineering at the University of Basel and from 2021 he is Director of the DBM. From 2004 to 2009 he was the first president of the European section of the Tissue Engineering Regenerative Medicine International Society (TERMIS), where he now coordinates the Strategic Alliance Committee. In 2018 he was elected as member of the Swiss Academy of Medical Sciences.
He is currently Chair of the ‘Mesenchymal Stromal Cell Committee’, member of the ‘Orthopaedics and Musculoskeletal Committee’ of the International Society for Cell & Gene Therapy (ISCT) and member of the editorial boards of 6 international journals.